Longboard pharmaceuticals' presence at american epilepsy society (aes) annual meeting reinforces ongoing commitment to the rare epilepsy community

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for lp352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (dees), in poster sessions at the 2023 aes annual meeting. longboard will also host a s.
LBPH Ratings Summary
LBPH Quant Ranking